Company Overview - ANEW MEDICAL, INC. is a biopharmaceutical technology company focused on developing disruptive therapies for central nervous system and neurodegenerative diseases [2][6] - The company specializes in patented, novel disease-modifying technologies, including protein, gene, and cell therapies for age-related disorders such as Alzheimer's and Parkinson's Disease [6] Business Combination - ANEW MEDICAL, INC. has completed a business combination with Redwoods Acquisition Corp., resulting in the combined entity being named "ANEW MEDICAL, INC." [2][3] - The shares and warrants of the combined company are expected to begin trading on the Nasdaq Global Market under the tickers "WENA" and "WENAW" respectively [1][2] Leadership Comments - Dr. Joseph Sinkule, Founder and CEO of ANEW, expressed gratitude towards RWOD personnel and advisors for their efforts in completing the business combination and emphasized the company's access to a larger international investor pool [3] - Jiande Chen, CEO of RWOD, highlighted the potential of ANEW in developing gene therapies for neurodegenerative diseases and aging-related conditions [4] Key Technologies and Assets - ANEW holds worldwide rights to several platform technologies, including a library of melanocortin peptides and a patented medical device called Nanoject™, designed for safe and painless self-injection of various medications [6] - The company aims to announce several key milestones achieved over the past year in the development of its major platform technologies [3]
ANEW MEDICAL, INC. and REDWOOD ACQUISITION CORP. ANNOUNCE CLOSING OF THEIR BUSINESS COMBINATION